[Preoperative hepatic and regional arterial infusion chemotherapy in the prevention of liver metastasis after colorectal cancer surgery]

Zhonghua Yi Xue Za Zhi. 2006 Jan 10;86(2):88-92.
[Article in Chinese]

Abstract

Objective: To investigate the effects of preoperative hepatic and regional arterial infusion chemotherapy (PHRAIC) in the prevention of liver metastasis of colorectal cancer after surgery.

Methods: 110 patients of colorectal cancer underwent perfusion of 3 anti-tumor drugs into the hepatic artery and nutrient artery of the tumor respectively, radical surgery of the colorectal cancer 7 days after, and then general venous chemotherapy 3 weeks after operation, 112 patients underwent radical surgery of the colorectal cancer and general venous chemotherapy 3 weeks after operation. Follow-up was carried out every month with a follow-up period of 34 months +/- 3 months.

Results: There were no significant difference in post-operational complications between these 2 groups. The 3-year liver metastasis rate, 3-year tumor-free survival rate, overall survival rate, and median survival time of the stage III patients in the PHRAIC group were 12.7%, 82.3%, 87.7%, and 40 months +/- 5 months, all significantly better than those in the control group (28.3%, 58.7%, 75.5%, and 36 months +/- 3 months respectively, P < 0.05 or P < 0.01).

Conclusion: PHRAIC reduces the liver metastasis of colorectal cancer after radical surgery and improves the survival of the stage III patients.

Publication types

  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Cancer, Regional Perfusion
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Colorectal Surgery
  • Female
  • Follow-Up Studies
  • Hepatic Artery
  • Humans
  • Liver Neoplasms / prevention & control*
  • Liver Neoplasms / secondary
  • Male
  • Middle Aged
  • Premedication
  • Preoperative Care / methods*
  • Survival Analysis

Substances

  • Antineoplastic Agents